Seminars in Oncology
Volume 29, Issue 3 , Pages 274-279, June 2002

Pathological and molecular assessment of sentinel lymph nodes in solid tumors

Departments of Surgery and Pathology, Vermont Cancer Center, College of Medicine, University of Vermont, Burlington, VT.

Abstract 

Sentinel nodes (SNs) are the first set of nodes to receive drainage and cancer cells from a primary tumor. While there may be a single SN, frequently there are one to three or more SNs. The development of sentinel node surgery over the last decade has led to dramatic changes in the surgical approach to regional nodes draining solid tumors. The surgeon can now identify, to a level of accuracy previously impossible, the regional nodes most likely to be involved with cancer in any individual patient. This new capability comes at a cost; the principles guiding the extent of nodal surgery must be completely re-examined. The extent of surgical resection required to achieve each of the goals of regional node surgery—(1) establishing prognosis, (2) obtaining regional control, and (3) improving overall survival—may no longer be simply the default “regional node resection” and may vary depending on the clinical goals. Inseparable from this new surgical technology is the methodology employed for pathologic evaluation of SNs. It is critical that pathologists and clinicians conduct definitive clinical research directed toward defining the role and impact that SN surgery has on each of these surgical goals. Semin Oncol 29:274-279. Copyright 2002, Elsevier Science (USA). All rights reserved.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Address reprint requests to David Krag, MD, University of Vermont, College of Medicine, Given Bldg, Room E309, Burlington, VT 05405.

PII: S0093-7754(02)50183-4

doi:10.1053/sonc.2002.32894

Seminars in Oncology
Volume 29, Issue 3 , Pages 274-279, June 2002